Intercept Pharmaceuticals (NASDAQ:ICPT) received a $100.00 target price from stock analysts at Oppenheimer in a note issued to investors on Monday. The firm presently has a “hold” rating on the biopharmaceutical company’s stock. Oppenheimer’s price objective points to a potential downside of 10.38% from the company’s current price.
ICPT has been the subject of several other reports. Needham & Company LLC reissued a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Thursday, August 2nd. Wedbush reissued a “buy” rating and set a $203.00 price target (down from $217.00) on shares of Intercept Pharmaceuticals in a research report on Friday, August 3rd. BidaskClub cut Intercept Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 22nd. ValuEngine raised Intercept Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 2nd. Finally, Royal Bank of Canada reissued a “buy” rating and set a $115.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, August 3rd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $136.17.
Shares of NASDAQ ICPT opened at $111.58 on Monday. Intercept Pharmaceuticals has a 52 week low of $51.05 and a 52 week high of $133.74. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 2.48. The company has a market cap of $3.74 billion, a P/E ratio of -7.76 and a beta of -1.94.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($2.58) EPS for the quarter, beating the consensus estimate of ($2.83) by $0.25. Intercept Pharmaceuticals had a negative return on equity of 614.15% and a negative net margin of 215.30%. The firm had revenue of $43.58 million during the quarter, compared to analysts’ expectations of $41.26 million. During the same period in the prior year, the firm posted ($3.46) earnings per share. The business’s quarterly revenue was up 41.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Intercept Pharmaceuticals will post -10.83 EPS for the current year.
In other news, insider David Shapiro sold 4,917 shares of the firm’s stock in a transaction that occurred on Wednesday, September 5th. The stock was sold at an average price of $111.43, for a total value of $547,901.31. Following the completion of the sale, the insider now directly owns 42,196 shares of the company’s stock, valued at $4,701,900.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 4.90% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the company. US Bancorp DE increased its stake in shares of Intercept Pharmaceuticals by 821.6% during the first quarter. US Bancorp DE now owns 1,751 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 1,561 shares during the period. Tocqueville Asset Management L.P. bought a new position in shares of Intercept Pharmaceuticals during the second quarter worth approximately $252,000. Sheaff Brock Investment Advisors LLC bought a new position in shares of Intercept Pharmaceuticals during the second quarter worth approximately $264,000. Opus Point Partners Management LLC increased its stake in shares of Intercept Pharmaceuticals by 19.0% during the first quarter. Opus Point Partners Management LLC now owns 4,496 shares of the biopharmaceutical company’s stock worth $277,000 after purchasing an additional 717 shares during the period. Finally, United Services Automobile Association bought a new position in shares of Intercept Pharmaceuticals during the second quarter worth approximately $280,000. Institutional investors own 69.38% of the company’s stock.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR).
Featured Story: How to Track your Portfolio in Google Finance
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.